OptimizeRx (OPRX) Equity Average (2016 - 2025)
Historic Equity Average for OptimizeRx (OPRX) over the last 16 years, with Q3 2025 value amounting to $120.8 million.
- OptimizeRx's Equity Average rose 257.6% to $120.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $120.8 million, marking a year-over-year increase of 257.6%. This contributed to the annual value of $121.8 million for FY2024, which is 360.68% down from last year.
- According to the latest figures from Q3 2025, OptimizeRx's Equity Average is $120.8 million, which was up 257.6% from $117.8 million recorded in Q2 2025.
- In the past 5 years, OptimizeRx's Equity Average ranged from a high of $135.9 million in Q2 2022 and a low of $85.9 million during Q1 2021
- In the last 5 years, OptimizeRx's Equity Average had a median value of $121.8 million in 2024 and averaged $121.7 million.
- Its Equity Average has fluctuated over the past 5 years, first soared by 18292.89% in 2021, then crashed by 1422.68% in 2023.
- OptimizeRx's Equity Average (Quarter) stood at $129.1 million in 2021, then dropped by 0.97% to $127.8 million in 2022, then decreased by 5.09% to $121.3 million in 2023, then decreased by 4.61% to $115.7 million in 2024, then grew by 4.36% to $120.8 million in 2025.
- Its Equity Average was $120.8 million in Q3 2025, compared to $117.8 million in Q2 2025 and $116.6 million in Q1 2025.